Biotech entity

National Ethics Committee (DRC)

organization

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ACOREP, the most common co-covered peer. We currently track 1 Biotech story that mention National Ethics Committee (DRC), all published on July 13, 2026.

Last mentioned: Jul 13, 2026

RSS updates
Share

Entity pulse

Recent coverage · National Ethics Committee (DRC)

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about National Ethics Committee (DRC)

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ACOREP, the most common co-covered peer. We currently track 1 Biotech story that mention National Ethics Committee (DRC), all published on July 13, 2026. Each carries 3 original sources on average.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering National Ethics Committee (DRC). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Ethics Approval Received

    NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.

  2. Outbreak Worsens

    DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.

Stories mentioning National Ethics Committee (DRC) 1

Clinical Trials Positive

NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender

NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.

3 sources

Source: newjerseytelegraph.com · hawaiitelegraph.com

National Ethics Committee (DRC) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.